Resveratrol has been investigated in several phase II clinical trials, demonstrating its ability to modulate cerebrospinal fluid biomarkers (e.g., Aβ40, tau) and exert mild cognitive benefits in patients with mild to moderate Alzheimer’s disease, despite limitations in bioavailability [163]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.